Educational guide
Cartalax Overview, Dosing & Safety | Peptide Database
Cartalax (AED peptide) Bioregulatory Tripeptide | Cartilage & Connective Tissue Support Community Research Join others researching Cartalax — share findings, ask questions, and learn from real experiences Synthetic tripeptide developed by Professor Vladimir Kh
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Cartalax (AED peptide)
Bioregulatory Tripeptide | Cartilage & Connective Tissue Support
Community Research
Join others researching Cartalax — share findings, ask questions, and learn from real experiences
Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.
Modulates cell proliferation, suppresses apoptosis, affects fibroblast activity, reduces senescence markers, and influences extracellular matrix preservation.
Molecular Data
Alanine
Position 1
Glutamic Acid
Position 2
Asp (AED)
Position 3
Research Indications
Clinical efficacy shown in osteochondrosis, osteoarthritis, and osteoporosis treatment.
Supports cartilage maintenance and joint function.
Supports bone and connective tissue healing.
Increased Ki-67 expression with suppressed apoptosis in young and aged cells.
Enhances collagen synthesis in connective tissue.
Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.
Dosing Protocols
Capsule form; do not chew, swallow whole with water during meals.
Joint Support
100-200mcg (1-2 capsules)
1-2x daily with meals
Oral
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
No reported side effects in Russian clinical use when taken properly
Well-tolerated in elderly patients
Stop Signs - Discontinue if:
Allergic reactions
Digestive upset (rare with proper administration)
No improvement after 3 months
Unexpected symptoms
Contraindications
Pregnancy and breastfeeding
Active cancer (theoretical proliferation risk)
Quality Checklist
Good Signs
Professional Russian packaging with holographic seals
Exactly 0.1mg (100mcg) AC-4 peptide complex per capsule
Clear Russian/English instructions specifying 'with meals'
Warning Signs
Proper documentation required for authenticity
Import verification needed
Bad Signs
Missing holographic seals or professional packaging
Unclear dosing instructions
Frequently Asked Questions
How does Cartalax help cartilage if cartilage doesn't have blood vessels to deliver it?
Cartalax works through systemic effects on fibroblasts and gene expression. Once in circulation, it reaches fibroblasts throughout connective tissue, stimulating collagen production and suppressing matrix-degrading enzymes like MMP-9. This systemic fibroblast activation supports cartilage maintenance and collagen preservation even in avascular cartilage.
Can Cartalax reverse osteoarthritis or just prevent progression?
Russian clinical studies show efficacy in established osteoarthritis, osteochondrosis, and osteoporosis treatment. However, 'reverse' is overstated—Cartalax supports tissue repair and slows degeneration better than it rebuilds severely damaged cartilage. Results are best when cartilage damage is moderate, not advanced.
How long before joint pain improves on Cartalax?
Week 1-2 establishes baseline; minimal noticeable changes. Week 3-4 brings gradual improvement in joint comfort. Month 2 shows noticeable mobility improvements. Month 3 achieves maximum therapeutic effect. Results are cumulative with repeat cycles; 1-3 month cycles repeated annually produce best long-term joint health.
Is Cartalax safe for long-term use or does it carry cancer risk from cell proliferation?
Cartalax increases fibroblast proliferation while suppressing apoptosis. Theoretical concern exists regarding uncontrolled cell growth, but Russian clinical practice spanning decades shows no documented malignancy risk. Avoid use in active cancer; for healthy individuals, cyclic use (1-3 months on, breaks between) minimizes theoretical proliferation risk.
References
Human skin fibroblasts; 72 hours at 20 nM. Increased Ki-67 expression with suppressed apoptosis in young and aged cells.
Renal epithelial cells; 7 days. Reduced pro-apoptotic p53 expression in aging kidney cells.
Human subjects; 1-3 months with 0.1mg capsules daily. Efficacy in osteochondrosis, osteoarthritis, and osteoporosis treatment.
Fibroblast cultures; 5 days at 20 nM. Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.
Related Peptides
Different mechanisms; no direct interaction.
Distinct action pathways; may complement effects.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.